Research progress of new target antipsychotic drug-SEP-363856
10.3760/cma.j.cn113661-20200824-00376
- VernacularTitle:新靶点抗精神病药SEP-363856研究进展
- Author:
Yue ZHANG
1
;
Yunai SU
1
;
Tianmei SI
1
Author Information
1. 北京大学第六医院 北京大学精神卫生研究所 国家精神心理疾病临床医学研究中心（北京大学第六医院） 国家卫生健康委员会精神卫生学重点实验室（北京大学） 100191
- Publication Type:Journal Article
- Keywords:
Antipsychotic agents;
Receptors, dopamine;
Receptor, serotonin, 5-HT1A;
SEP-363856;
Trace amine associated receptor 1
- From:
Chinese Journal of Psychiatry
2021;54(3):224-228
- CountryChina
- Language:Chinese
-
Abstract:
Schizophrenia is a common chronic disabling mental disorder with complex etiology and pathological mechanism. Over the past 70 years, antipsychotics have primarily acted on D 2 receptors, with poor response to negative symptoms and cognitive impairment and more adverse effects, which have significantly affected patient compliance and functional recovery. Therefore, the development of new-targeted antipsychotic drugs is particularly urgent. SEP-363856 is a non-D 2-receptor-binding drug for the treatment of schizophrenia which is found by phenotypic screening strategies, and the pharmacological mechanism has not been fully elucidated. Preclinical data suggest that SEP-363856 may active Trace amine associated receptor 1 (TAAR1) and 5-HT 1A receptors, and the discovery of this drug shed light on new treatment options for schizophrenic. This review provides an introduction of the development of SEP-363856, including preclinical findings and the latest clinical trial data, to help readers understand this new antipsychotic drug.
